Nationwide Coffee Recall as Products May Contain Glass
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products sold nationwide over concerns they may contain glass fragments.
The recalled products were sold and distributed exclusively in Dollar General stores between July 9 and 21, the company said in an announcement published by the U.S. Food and Drug Administration (FDA).
Newsweek contacted Dollar General Corporation for comment via email outside of regular office hours.
Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination.
Stock image. Dollar General Corporation has recalled select lots of its Clover Valley Instant Coffee products over concerns of glass contamination.
Lino Mirgeler/picture-alliance/dpa/AP
Why It Matters
The FDA said that ingesting glass fragments "may cause injury to the consumer."
"These injuries may include damage to teeth, laceration of the mouth and throat, or perforation of the intestine," it said.
What To Know
The recall applies to three lots of Dollar General's eight ounce Clover Valley Instant Coffee, with the UPC code: 876941004069.
The affected lot numbers and best-by dates are the following:
L-5163 - best-by: 12/13/2026
L-5164 - best-by: 12/13/2026
L-5165 - best-by: 12/14/2026
The recalled products were sold and distributed in every state other than Alaska and Hawaii, the FDA said.
The recall was initiated after a customer notified Dollar General about the potential issue. As of August 12, no illnesses or injuries had been reported in connection with the products.
The company said it was investigating the source of the glass contamination. It also encouraged customers who purchased the affected products to discard them and contact the company for a full refund.
What People Are Saying
Dollar General Corporation said in a recall announcement that it is "investigating the source of the glass contamination and apologizes for any inconvenience caused."
Dr. Mark Fischer, regional medical director at International SOS, told Newsweek previously: "It can be dangerous to consume metals or other foreign objects found in food... [They] can cause cuts or internal injury and may need to be removed via a surgical procedure. If you swallow any foreign objects, it's best to consult a healthcare professional."
What Happens Next
Dollar General said it was investigating the source of the glass contamination.
FDA inspectors are expected to carry out a hazard assessment before issuing one of three risk levels. The three classifications are:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Businesses in Colchester and Tendring told to improve after poor hygiene ratings
HYGIENE is important to the success of any company that deals with food. Over the last couple of months, there are five businesses in Colchester and Tendring which have received poor ratings after being inspected by the Food Standards Agency (FDA). The FDA inspects a business and then gives it a rating between zero and five, with the latter being the best. The ratings are given on the business's hygiene and safety, structural compliance and confidence in management. The ratings are routinely updated and can change after each inspection. At of time of writing, these are the businesses that have scored the lowest ratings between May to July. Happy House in Colchester Road, St Osyth Rating: two – Improvement necessary Last inspection date: May 16 The British Grenadier in Military Road, Colchester Rating: one – Major improvement necessary Last inspection date: May 22 Golden Wok Chinese Takeaway in Tower Street, Brightlingsea Rating: two – Improvement necessary Last inspection date: June 13 Royal Gurkha lounge in Magdalen Street, Colchester Rating: two – Improvement necessary Last inspection date: June 18 Bodrum Grill in Crouch Street, Colchester Rating: zero – Urgent improvement necessary Last inspection date: July 3
Yahoo
15 hours ago
- Yahoo
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced that it is monitoring a safety issue with Boston Scientific Corporation's ENDOTAK RELIANCE defibrillation leads, which are used with implantable cardioverter-defibrillators to prevent sudden cardiac death. Earlier this year, the company sent a letter to healthcare providers on July 24, warning that calcification of the leads' expanded polytetrafluoroethylene/ePTFE coating could lead to a gradual increase in low-voltage shock impedance/LVSI. This can reduce the effectiveness of life-saving shocks and even result in patient death. A surgeon examining a patient's brain in an operating room, paramedics nearby. The affected leads were manufactured and distributed between 2002 and 2021 and are no longer available. As of July 24, Boston Scientific had reported 386 serious injuries and 16 deaths linked to this issue. The FDA has categorized this as a potentially high-risk problem and is actively reviewing data to determine further regulatory action. Boston Scientific Corporation (NYSE:BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It has 2 segments: MedSurg and Cardiovascular. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
21 hours ago
- Business Insider
Tonix announces FDA approval of Tonmya for treatment of fibromyalgia
Tonix Pharmaceuticals (TNXP) Holding Corp. announced that the FDA approved Tonmya for the treatment of fibromyalgia in adults. Tonmya is a first-in-class, non-opioid, once-daily bedtime analgesic with a unique sublingual formulation that is designed for rapid absorption into the bloodstream. Tonmya is the first new FDA-approved therapy for the treatment of fibromyalgia in over 15 years. The approval incorporated efficacy from two double-blind, randomized, placebo-controlled, Phase 3 clinical trials of nearly 1,000 patients in total that evaluated Tonmya as a bedtime treatment for fibromyalgia. Across both Phase 3 trials, Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks, the primary endpoint. Additionally, a greater percentage of study participants taking Tonmya experienced a clinically meaningful (greater than or equal to30%) improvement in their pain after three months, compared to placebo. Across three Phase 3 clinical trials with over 1,400 patients evaluated, Tonmya was generally well tolerated. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year. Elevate Your Investing Strategy:
